الفهرس 
Hepatitis C virus, an overviewOnly 14 pages are availabe for public view
 |  | from | 196 |  |  |
| | | from | 196 | | |
Abstract
PegIFN plus RBV was the standard treatment for chronic HCV until recently and is continuing to be used in combination with directacting antiviral agents. Anemia has been observed in up to 30% of treated patients with PegIFV/RBV, often leading to symptoms (eg, fatigue), RBV dose reduction, and/or treatment discontinuation. Because of RBV dose reduction, on-treatment RBV exposure is supposed to be lower in anemic patients compared with non-anemic patients, and might affect the treatment outcome as some studies had shown that RBV dose reduction had been linked to lower SVR rates. Erythropoiesis-stimulating agents (ESAs) have been used in up to 15% of patients undergoing HCV treatment to maintain RBV dosing and improve patients’ health-related quality of life (HRQL).